Skip to main content
Premium Trial:

Request an Annual Quote

Predicting New Regulatory Requirements? There's a Game We Wouldn't Want to Play

Over at 23andMe's corporate blog The Spittoon, founders Linda Avey and Anne Wojcicki address the recent delays customers have experienced in getting results. What's more interesting than the slowdown is the reason for it: while consumer genomics companies are not yet regulated, 23andMe has opted to move its sample processing operation to a high-complexity, CLIA-certified lab. "Though CLIA certification and oversight are appropriate for specific health and disease-related testing, we are complying with these guidelines to be consistent with other types of laboratory testing," Wojcicki writes in the post.

At his Genetic Future blog, Daniel MacArthur wonders why 23andMe switched, when CLIA certification isn't required. "I don't know enough about the regulatory environment in the US to guess at whether this move is simply in order to stay ahead of the shifting demands of regulatory agencies," he writes, "or whether it heralds a move towards a more clinical focus (something the company has explicitly steered away from so far)."

 

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.